TY - JOUR
T1 - Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
AU - Iqbal, Madiha
AU - Jagadeesh, Deepa
AU - Chavez, Julio
AU - Khurana, Arushi
AU - Rosenthal, Allison
AU - Craver, Emily
AU - Epperla, Narendranath
AU - Li, Zhuo
AU - Isufi, Iris
AU - Awan, Farrukh T.
AU - Dholaria, Bhagirathbhai R.
AU - Maakaron, Joseph E.
AU - Sandoval-Sus, Jose D.
AU - Mishra, Rahul
AU - Saha, Aditi
AU - Annunzio, Kaitlin
AU - Bhaskar, Shakthi T.
AU - Sumransub, Nuttavut
AU - Fijalka, Andrew
AU - Ivanov, Stanislav A.
AU - Lin, Yi
AU - Kharfan-Dabaja, Mohamed A.
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature Limited 2023.
PY - 2024/2
Y1 - 2024/2
N2 - Outcomes are poor for patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) post chimeric antigen receptor T-cell (CAR-T) therapy. Two CD19-directed therapies, tafasitamab- cxix plus lenalidomide (tafa-len) and loncastuximab tesirine (loncaT) are approved in R/R LBCL. The efficacy of these CD19 directed therapies in patients who relapse after CD19 directed CAR-T (CD19-CART) therapy is not well understood. We conducted a multi-center study of patients with R/R LBCL that received either tafa-len or loncaT at any timepoint for R/R disease after CD19-CART therapy. Fifty-three patients were included in this study with the median follow up of 56 (9.1–199) weeks from CAR-T infusion. Median number of systemic therapies pre–CAR-T therapy was 3 (range: 1–6); axicabtagene ciloleucel was the most utilized CAR-T product (n = 32,60%). Median time from CAR-T therapy to tafa-len or loncaT was 7.3 (1.2–38.2) months with median number of lines of therapy between CAR-T therapy and these regimens of 1 (0–5). Combined overall response rate and complete response rates were 27% and 10%, respectively. Median duration of response was 13.3 (2.1–56.7) weeks. In this real-world study, the use of currently approved CD19-directed therapies to treat R/R LBCL after CD19-CAR-T therapy showed limited clinical activity and duration of responses.
AB - Outcomes are poor for patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) post chimeric antigen receptor T-cell (CAR-T) therapy. Two CD19-directed therapies, tafasitamab- cxix plus lenalidomide (tafa-len) and loncastuximab tesirine (loncaT) are approved in R/R LBCL. The efficacy of these CD19 directed therapies in patients who relapse after CD19 directed CAR-T (CD19-CART) therapy is not well understood. We conducted a multi-center study of patients with R/R LBCL that received either tafa-len or loncaT at any timepoint for R/R disease after CD19-CART therapy. Fifty-three patients were included in this study with the median follow up of 56 (9.1–199) weeks from CAR-T infusion. Median number of systemic therapies pre–CAR-T therapy was 3 (range: 1–6); axicabtagene ciloleucel was the most utilized CAR-T product (n = 32,60%). Median time from CAR-T therapy to tafa-len or loncaT was 7.3 (1.2–38.2) months with median number of lines of therapy between CAR-T therapy and these regimens of 1 (0–5). Combined overall response rate and complete response rates were 27% and 10%, respectively. Median duration of response was 13.3 (2.1–56.7) weeks. In this real-world study, the use of currently approved CD19-directed therapies to treat R/R LBCL after CD19-CAR-T therapy showed limited clinical activity and duration of responses.
UR - http://www.scopus.com/inward/record.url?scp=85176747640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176747640&partnerID=8YFLogxK
U2 - 10.1038/s41409-023-02148-4
DO - 10.1038/s41409-023-02148-4
M3 - Article
C2 - 37973893
AN - SCOPUS:85176747640
SN - 0268-3369
VL - 59
SP - 211
EP - 216
JO - Bone marrow transplantation
JF - Bone marrow transplantation
IS - 2
ER -